Cure My Disease

Don't miss your cure!

 Log in / Sign up

Retraining the senses to fight chemotherapy nerve damage

NCT ID NCT05382520

Symptom relief Sponsor: Assaf-Harofeh Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether a sensory rehabilitation program, guided by physiotherapists, can reduce nerve pain and improve balance in people with chemotherapy-induced peripheral neuropathy (CIPN). Participants are adults who finished chemotherapy more than three months ago and report neuropathy symptoms. The program uses questionnaires and physiotherapy practice to retrain sensory detection and movement. The study measures changes in pain, balance, and sensory function using several assessment tools.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sensory rehabilitation physiotherapy program
What this could lead to
If it works, this could point toward a non-drug therapy to ease nerve pain and improve balance in people with chemotherapy-induced neuropathy.
What could go wrong
This is a very small trial with only 12 participants, so results may not apply broadly. The therapy may not reduce symptoms, and benefits could be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Aug 2022

Finished

Dec 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 and over who suffer from chemotherapy-induced neuropathy (CIPN), according to the patient's report, more than 3 months since the end of the chemotherapy treatment. Exclusion Criteria: 1. Sensory damage / neuropathy that existed even before the start of chemotherapy 2. Incidents of recurrent falls even before the start of chemotherapy (over 2 falls for 6 months) 3. Central nervous system involvement 4. Major pre-morbid orthopedic lower limb impairment 5. Hebrew language not sufficient for assessment and treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIPN

Contacts and locations

Locations

  • Shamir medical center

    Beer Yaaqov, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.